Physician profile
Neil E Doherty
NPI 1871562017
$8,696.77
in general payments reported to CMS, 2019-2025
27 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $711 · 2021: $1,307 · 2022: $1,104 · 2023: $2,816 · 2024: $874 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631 · Travel and Lodging: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.16 |
| Travel and Lodging | $1,761.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,210.01 | 2023 | Micra |
| Amarin Pharma, INC. | $776.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $696.76 | 2019-2025 | |
| Amgen INC. | $640.86 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $635.67 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $504.41 | 2019-2023 | Seglentis |
| Merck Sharp & Dohme LLC | $486.80 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.33 | 2019-2024 | Jardiance |
| Edwards Lifesciences Corporation | $278.85 | 2019-2025 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $268.49 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $252.49 | 2020-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $233.90 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $176.16 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $166.83 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $164.21 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $164.00 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.80 | 2019-2023 | Lifevest |
| Abbott Laboratories | $98.48 | 2019-2024 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $84.52 | 2019-2024 | |
| Baxter Healthcare | $83.52 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $61.39 | 2025 | Amvuttra |
| Bardy Diagnostics, INC. | $51.08 | 2021-2022 | |
| Novo Nordisk INC | $44.81 | 2021-2025 | Ozempic, Rybelsus |
| Abiomed | $44.07 | 2025 | |
| Medtronic Vascular, INC. | $30.10 | 2020 | |
| Pfizer INC. | $28.85 | 2025 | |
| Heartflow, INC. | $28.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.